EVIDENCE OF PLATELET-ACTIVATING-FACTOR IN NASAL POLYPS

被引：6

作者：

FURUKAWA, M ^{[1
]}

YAMASHITA, T ^{[1
]}

KUMAZAWA, T ^{[1
]}

SATOUCHI, K ^{[1
]}

SAITO, K ^{[1
]}

机构：

[1] KANSAI MED UNIV,DEPT OTOLARYNGOL,FUMIZONOCHO,MORIGUCHI,OSAKA 570,JAPAN

来源：

ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES | 1992年 / 54卷 / 01期

关键词：

PLATELET-ACTIVATING FACTOR; NASAL POLYP; CHRONIC SINUSITIS;

D O I：

10.1159/000276255

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Platelet-activating factor (PAF) was measured in human nasal polyps obtained from patients with chronic sinusitis. PAF was quantitated by platelet-aggregating activity and was found to be 7.8 +/- 1.8 pg/gg phosphorus of polyp phospholipid (mean +/- SE; n = 23). In the polyps, phosphatidylcholine constituted 30% of the total phospholipids, of which 8.5% was the ether-linked type. Incubations of replicates of the fresh polyps in Tyrode's solution in the presence of calcium ionophore A23187 and antihuman immunoglobulin E resulted in 295 and 65% increases in the amount of PAF, respectively. Thus, nasal polyps- in humans with chronic sinusitis possess PAF and have the potential to produce PAF upon stimulation. The participation of PAF in nasal polyp formation is discussed.

引用

页码：29 / 32

页数：4

共 23 条

[1]

Caplin I., Haynes J.T., Spahn J., Arc nasal polyps an allergic phenomenon?, Ann Allergy, 29, pp. 631-635, (1971)

[2]

Baumgarten C., Kunkel G., Rudolph R., Staud R.D., Sperner I., Gclderblom H., Histopatholog-ical examinations of nasal polyps of different etiology, Arch Otorhinolaryngol, 226, pp. 187-197, (1980)

[3]

Pinckard R.N., Ludwig J.C., McManus L.M., Platelet-activating factor, Inflammation: Basic Principles and Clinical Correlates. New York, pp. 139-167, (1988)

[4]

Lee T.-C., Lenihan D.J., Malone B., Roddy L.L., Wasserman S., Increased biosynthesis of platelet-activating factor in activated human eosinophils, J Biol Chem, 259, pp. 5526-5530, (1984)

[5]

Betz S.J., Henson P.M., Production and release of platelet-activating factor (PAF): Dissociation from degranulation and superoxide production in the human neutrophil, J Immunol, 125, pp. 2756-2763, (1980)

[6]

Schleimer R.P., MacGlashan D.W., Peters S.P., Pinckard R.N., Adkinson N.F., Liechtenstein I.M., Characterization of inflammatory mediator release from purified human lung mast cells, Am Rev Respir Dis, 133, pp. 614-617, (1986)

[7]

McManus L.M., Hanahan D.J., Pinckard R.N., Human platelet stimulation by acetyl glyceryl ether phosphorylcholine, J Clin Invest, 67, pp. 903-906, (1981)

[8]

Shaw J.O., Pinckard R.N., Ferrigni K.S., McManus L.M., Hanahan D.J., Activation of human neutrophils with l-O-hexadecyl/octa-decyl-2-acetyl-, v«-glyceryl-3-phosphorylcholine (platelet activating factor), J Immunol, 127, pp. 1250-1255, (1981)

[9]

Wardlaw A.J., Moqbel R., Cromwell O., Kay A.B., Platelet-activating factor for human eosinophils, J Clin Invest, 78, pp. 1701-1706, (1986)

[10]

Humphery D.M., McManus L.M., Satouchi K., Hanahan D.J., Pinckard R.N., Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues, Lab Invest, 46, pp. 422-427, (1982)

← 1 2 3 →